Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
ESSA Pharma Inc
NASDAQ EPIX
Data sourced from
and
and
ESSA Pharma Inc Net Income is NA for the quarter ending March 31, 2024. Net Income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
-
ESSA Pharma Inc Net Income for the quarter ending March 31, 2023 was USD -7.30 M, a 32.76% change year over year.
-
ESSA Pharma Inc Net Income for the quarter ending March 31, 2022 was USD -10.85 M, a 16.28% change year over year.
-
ESSA Pharma Inc Net Income for the quarter ending March 31, 2021 was USD -12.97 M, a -38.57% change year over year.
-
ESSA Pharma Inc Net Income for the quarter ending March 31, 2020 was USD -9.36 M, a -172.79% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: EPIX
| CEO | Dr. David Ross Parkinson M.D. |
| IPO Date | July 9, 2015 |
| Location | Canada |
| Headquarters | 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 |
| Employees | 50 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email